Danny Cohn still remembers the first patient who walked into his clinic after receiving the experimental CRISPR infusion—swelling-free, hopeful, and for the first time in decades, not living in fear of the next attack. That moment, now echoed across 80 lives in a landmark Phase III trial, marks a turning point in genetic medicine. At Amsterdam UMC, Cohn and his team have led the world’s first large-scale, double-blind study of in vivo CRISPR therapy, delivering not just data, but deliverance for people with hereditary angioedema—a rare, painful disorder that causes unpredictable and potentially life-threatening swelling episodes.
This condition, driven by a faulty gene, has long demanded relentless preventive medication, constant vigilance, and a readiness to treat at the first sign of trouble. But the results of this trial, presented at the European Academy of Allergy and Clinical Immunology congress in Istanbul and published in The New England Journal of Medicine, suggest a new reality: a single intravenous infusion could offer lasting protection. Of the 80 patients enrolled, half received lonvoguran-ziclumeran, a CRISPR-based therapy designed to correct the genetic root of the disease inside the body—no cells removed, no surgeries required.
Between weeks 5 and 28 after treatment, the impact was staggering. Patients receiving the therapy experienced an 87% relative reduction in attacks. Even more striking, 62% of them remained completely attack-free—compared to just 11% in the placebo group. The need for rescue medication dropped by 89%, and severe attacks fell by 91%. Quality-of-life scores, often eroded by anxiety and unpredictability, showed marked improvement. And perhaps most reassuringly, the treatment proved safe: the most common side effects were mild—headache, fatigue, back pain—and no serious adverse events were reported in the treatment arm.
What makes this trial groundbreaking isn’t just its success, but its rigor. As the first in vivo CRISPR therapy to clear a Phase III double-blind trial, it meets the gold standard for regulatory approval. Follow-up data from earlier phases show the effects hold steady for at least four years, suggesting durability. "This study opens doors to in vivo CRISPR treatments for patients with other hereditary disorders," Cohn says, eyes on the horizon. "Inserting, deleting or repairing a gene—it is all possible with CRISPR technology."
For patients, this could mean liberation from daily pills, fewer hospital visits, and a future no longer shadowed by uncertainty. The approval of lonvoguran-ziclumeran could pave the way for CRISPR to move from lab curiosity to clinic standard—not just for angioedema, but for thousands living with inherited diseases. One infusion, one edit, one chance at a normal life.